Klotho Sensitizes Human Lung Cancer Cell Line to Cisplatin via PI3k/Akt Pathway

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Wang, Yan ^a   Chen, Lei ^a   Huang, Guochang ^b   He, Dongmei ^c   He, Juan ^a   Xu, Wei ^a   Zou, Chunying ^a   Zong, Feng ^a   Li, Yan ^a   Chen, Bo ^a   Wu, Shuanshuan ^a   Zhao, Weihong ^a   Wu, Jianqing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; KLOTHO PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG CANCER; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHROMONES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; GLUCURONIDASE; HUMANS; LENTIVIRUS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874326826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057391     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
3. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2011) Molecular mechanisms of cisplatin resistance. Oncogene.
4. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51.
5. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, et al. (2005) Suppression of aging in mice by the hormone Klotho. Science 309: 1829-1833.
6. Shiraki-Iida T, Aizawa H, Matsumura Y, Sekine S, Iida A, et al. (1998) Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett 424: 6-10.
7. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, et al. (2008) Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27: 7094-7105.
8. Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, et al. (2011) KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res 17: 4254-4266.
9. Chen B, Wang X, Zhao W, Wu J, (2010) Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res 29: 99.
10. Poh TW, Pervaiz S, (2005) LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res 65: 6264-6274.
11. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, et al. (2000) Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60: 5988-5994.
12. Shibata T, Kokubu A, Tsuta K, Hirohashi S, (2009) Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett 283: 203-211.
13. Hart JR, Vogt PK, (2011) Phosphorylation of AKT: a mutational analysis. Oncotarget 2: 467-476.
14. Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng XD, et al. (2006) Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10: 269-280.
15. Ju X, Katiyar S, Wang C, Liu M, Jiao X, et al. (2007) Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A 104: 7438-7443.
16. Hennenlotter J, Amend B, Vogel U, Renninger M, Springer C, et al. (2011) Differential Akt signalling in non-seminomatous testicular germ cell tumors. Anticancer Res 31: 3783-3788.
17. He XH, Li JJ, Xie YH, Tang YT, Yao GF, et al. (2004) Altered gene expression profiles of NIH3T3 cells regulated by human lung cancer associated gene CT120. Cell Res 14: 487-496.
18. Thompson JE, Thompson CB, (2004) Putting the rap on Akt. J Clin Oncol 22: 4217-4226.
19. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, et al. (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67: 6325-6332.
20. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, et al. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433.
21. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, et al. (2009) microRNA-205 regulates HER3 in human breast cancer. Cancer Res 69: 2195-2200.
22. Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, et al. (2011) BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and-resistant ovarian cancer cells. PLoS One 6: e20586.
23. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, et al. (2010) Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 3: ra81.
24. Zhao Z, Wang J, Tang J, Liu X, Zhong Q, et al. (2012) JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J 444: 291-301.
25. Brazil DP, Park J, Hemmings BA, (2002) PKB binding proteins. Getting in on the Akt. Cell 111: 293-303.
26. Yoeli-Lerner M, Toker A, (2006) Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5: 603-605.
27. Chin YR, Toker A, (2009) Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 21: 470-476.
28. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, et al. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275: 661-665.
29. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J, (1997) Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 16: 2783-2793.
30. Milane L, Ganesh S, Shah S, Duan ZF, Amiji M, (2011) Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J Control Release 155: 237-247.
31. Reed E, (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11: 6100-6102.
32. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, et al. (2004) The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787.
33. Eastman A, (1991) Mechanisms of resistance to cisplatin. Cancer Treat Res 57: 233-249.
34. Olaussen KA, Mountzios G, Soria JC, (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13: 284-289.
35. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
36. Hengartner MO, (2000) The biochemistry of apoptosis. Nature 407: 770-776.
37. Lee J, Jeong D-J, Kim J, Lee S, Park J-H, et al. (2010) The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Molecular Cancer 9: 109.
38. Rubinek T, Shulman M, Israeli S, Bose S, Avraham A, et al. (2011) Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Research and Treatment.
39. Pan J, Zhong J, Gan LH, Chen SJ, Jin HC, et al. (2011) Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. Tumor Biology 32: 729-735.